Dr. Reddy’s Laboratories has entered into a strategic collaboration with Immutep for the development and commercialization of Eftilagimod Alfa outside North America, Europe, Japan, and Greater China. Immutep will receive an upfront payment of USD 20 million and is eligible for up to USD 349.5 million in milestone payments, plus royalties. This partnership aims to deliver innovative cancer therapies to multiple markets.
Strategic Collaboration Overview
Dr. Reddy’s Laboratories and Immutep have announced a strategic collaboration. The agreement grants Dr. Reddy’s exclusive rights to develop and commercialize Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China. This arrangement signifies a step towards delivering first-in-class therapies for cancer treatment.
Financial Terms of the Agreement
Under the terms, Immutep will receive an upfront payment of USD 20 million. Furthermore, Immutep is eligible for potential regulatory development and commercial milestone payments reaching up to USD 349.5 million, in addition to double-digit royalties on commercial sales. These financial incentives align with successful development and sales performance.
Eftilagimod Alfa: A Novel Immunotherapy
Eftilagimod Alfa is a novel immunotherapy with the potential to set a new standard of care in combination with anti-PD-[L]1 and chemotherapy for non-small cell lung cancer. Its broad potential extends to other major cancers across multiple stages of disease. Dr. Reddy’s aims to leverage its expertise and market access to advance the commercialization of this cancer therapy.
Comments from Leadership
M.V. Ramana, CEO – Branded Markets (India & Emerging Markets), Dr. Reddy’s, stated, “This collaboration marks our continuous efforts to deliver first-in-class and innovative therapies for cancer treatment… Through this agreement, we look forward to leveraging our expertise and strong market access to advance the development and commercialization of this promising cancer therapy in the licensed markets.”
Marc Voigt, CEO of Immutep, added, “This agreement with Dr. Reddy’s marks a significant milestone for Immutep and further validates the potential of efti… Additionally, this partnership allows us to capture significant value for efti in the licensed markets, while retaining full rights in key markets.”
Source: BSE